Janet S. Graham - Publications

Correction: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal‑rich.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 14, 2026

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Journal: British journal of clinical pharmacology

Published: May 06, 2026

Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 23, 2025

FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: July 09, 2025

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.

Journal: Nature

Published: December 10, 2024

Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients.

Journal: Journal of cancer policy

Published: July 19, 2024

JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 27, 2023

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 10, 2023

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: August 18, 2022

Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice.

Journal: Health informatics journal

Published: February 23, 2022

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.

Journal: Clinical trials (London, England)

Published: January 27, 2022

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

Journal: Nature medicine

Published: January 11, 2022